Lajos Pusztai

Yale University

Full Professor(heuristic)

Breast Cancer Treatment Studies · Cancer Research

h-index114

i10-index450

Publications1,394

Citations69,663

Grants

12 total · 5 active

NIH #5P30CA016359-45

Genomics, Genetics and Epigenetics Research Program

Active

Amount: $97K
Period: 1997-07-01 → 2029-07-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #2P30CA016359-44

Genomics, Genetics and Epigenetics Research Program

Active

Amount: $82K
Period: 1997-07-01 → 2029-07-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #5R01CA286128-03

Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer

Active

Amount: $632K
Period: 2023-12-14 → 2028-11-30
PIs: 2
Est. capacity / PI: ~2 students

Awarded at ARIZONA STATE UNIVERSITY-TEMPE CAMPUS

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0033

PageRank within Cancer Research co-authorship network

Explore collaboration map

Admission Signals

New preprint: Multi-modal AI for comprehensive breast cancer prognostication2026-05-20
New paper: Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women (JAMA Oncology)2025-12-11
New NIH award: $632K — Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer2023-12-14
New NIH award: $644K — Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer2023-12-14
New NIH award: $671K — Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer2023-12-14
New NIH award: $97K — Genomics, Genetics and Epigenetics Research Program1997-07-01
New NIH award: $82K — Genomics, Genetics and Epigenetics Research Program1997-07-01

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0001-9632-6686

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 101

Multi-modal AI for comprehensive breast cancer prognosticationPreprint
Nature Communications · 2026-05-20 · 5 citations
A Practical Workflow for Correcting Kit-Specific Effects in Whole-Exome Sequencing DataPreprint
Preprints.org · 2026-04-21
Stage-related transcriptional changes in HR-positive/HER2-negative breast cancerPreprint
Research Square · 2025-12-12
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women
JAMA Oncology · 2025-12-11 · 3 citations
Mixed Molecular Subtypes Coexist in Estrogen Receptor Heterogeneous Primary Breast Cancers
JCO Precision Oncology · 2025-11-01
Abstract B030: Development of a novel antibody drug conjugate (ADC) targeting Nectin-2 on the surface of breast cancers
Molecular Cancer Therapeutics · 2025-10-22
Abstract C051: Emerging Novel Targets to treat non-responding HER2-negative breast cancer patients: The neoadjuvant I-SPY2 TRIAL 2300 patient Omics data and organoid studies
Molecular Cancer Therapeutics · 2025-10-22
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
Annals of Oncology · 2025-10-21 · 50 citations
Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial
Future Oncology · 2025-10-07
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer
npj Breast Cancer · 2025-09-29 · 1 citations
Correction: Associations amongst genes, molecules, cells, and organs in breast cancer metastasis
Clinical & Experimental Metastasis · 2025-09-19
Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer
Annals of Oncology · 2025-09-17 · 4 citations
Data from Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer
2025-09-15
Supplementary Figure S1 from Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast CancerPreprint
2025-09-15
Figure S3 from Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
2025-09-02
Table S2 from Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
2025-09-02
Figure S4 from Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
2025-09-02
Supplementary Materials and Methods from Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
2025-09-02
Figure S2 from Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
2025-09-02
Figure S1 from Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
2025-09-02

Open author page on OpenAlex →

Lajos Pusztai

Grants

Genomics, Genetics and Epigenetics Research Program

Genomics, Genetics and Epigenetics Research Program

Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer

All Grants

Genomics, Genetics and Epigenetics Research Program

Genomics, Genetics and Epigenetics Research Program

Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer

Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer

Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer

Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome

Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome

Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome

Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome

Preoperative chemotherapy for breast cancer

preoprative chemotherapy for breast cancer

Preoperative chemotherapy for breast cancer

Career Trajectory

Research Cluster Map

Potential Collaborators

Recent Publications